Table 2 Drug treatments administered to patients at baseline and at the end of the study period
From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study
Baseline | End of study | |
|---|---|---|
Anti-hypertensive agents | ||
Angiotensin receptor blocker | 5 | 5 |
Calcium channel blocker | 6 | 6 |
Alpha adrenergic blocker | 2 | 2 |
Beta blockers | 2 | 2 |
HMG-CoA reductase inhibitors | 0 | 0 |
Cinacalcet, n | 2 | 2 |
Oral vitamin D | 3 | 3 |
Intravenous vitamin D | 8 | 8 |
Calcium polystyrene sulfonate | 1 | 1 |